Compugen Ltd (CGEN) 8.19 $CGEN
Direction of Market Influences: Special Research on Insperity, Compugen, Aeropostale, Starwood Hotels & Resorts, and Coca-Cola
PR Newswire - Wed Feb 11, 8:10AM CST
Editor Note: For more information about this release, please scroll to bottom.
KO: 41.99 (-0.18), NSP: 48.91 (+1.20), CGEN: 8.19 (+0.08), ARO: 3.63 (+0.04), HOT: 78.55 (+0.67)
Compugen's (CGEN) CEO Anat Cohen-Dayag on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Feb 10, 12:49PM CST
CGEN: 8.19 (+0.08)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Tue Feb 10, 8:16AM CST
CAMT: 3.08 (+0.09), ZIOP: 9.64 (-0.35), XON: 39.30 (+1.05), BIOC: 1.41 (+0.22), KKR: 24.42 (+0.06), NBG: 1.61 (+0.18), ARO: 3.63 (+0.04), ANFI: 8.84 (-0.42), HOT: 78.55 (+0.67), COUP: 11.06 (-0.07), URBN: 38.47 (+0.27), VSTM: 7.93 (-0.44), SYN: 2.13 (+0.18), ANTH: 3.84 (+0.06), SALE: 16.41 (+0.13), CGEN: 8.19 (+0.08), DF: 16.19 (-0.11), CJJD: 2.59 (-0.01), MERU: 2.74 (-0.01)
Compugen reports 4Q loss
Automated Insights - Tue Feb 10, 6:36AM CST
TEL AVIV, Israel (AP) _ Compugen Ltd. (CGEN) on Tuesday reported a loss of $1.5 million in its fourth quarter.
CGEN: 8.19 (+0.08)
Compugen beats by $0.08, beats on revenue
Seeking Alpha - at Seeking Alpha - Tue Feb 10, 6:16AM CST
CGEN: 8.19 (+0.08)
Compugen Ltd. Reports Fourth Quarter and Calendar 2014 Results
Business Wire - Tue Feb 10, 6:10AM CST
Compugen Ltd. (NASDAQ: CGEN) today reported financial results for the fourth quarter and year ended December 31, 2014.
CGEN: 8.19 (+0.08)
Compugen: A Biotech With Many Rewarding Catalysts
Clinically Sound Investor - at Seeking Alpha - Tue Feb 10, 4:23AM CST
CGEN: 8.19 (+0.08)
Compugen Presents New Results Supporting CGEN-15049 as Potential Cancer Immunotherapy Target
Business Wire - Mon Feb 09, 6:14AM CST
Speaking today at the Keystone Symposia on Tumor Immunology in Banff, Canada, Arthur Machlenkin, PhD, Head of Immunology Group at Compugen Ltd. (NASDAQ: CGEN), presented new experimental results for CGEN-15049, a novel immune checkpoint protein discovered by the Company as a target for cancer immunotherapy. The new data presented for CGEN-15049 demonstrate expression of this protein on tumors isolated from ovarian cancer patients, both on the cancer cells and on immune cells within the tumor. Additional new data also demonstrate expression of CGEN-15049 on a similar population of tumor infiltrating immune cells in tumor-bearing mice. The collective data generated to date by Compugen support the ability of CGEN-15049 to affect key components of the immune system known to be involved in anti-tumor immune responses, supporting its potential as a promising target for immuno-oncology antibody therapy. Dr. Machlenkin's presentation at the Keystone Symposia also included experimental data for CGEN-15027, a different novel immune checkpoint candidate discovered by the Company.
CGEN: 8.19 (+0.08)
Compugen reports February 10
Seeking Alpha - at Seeking Alpha - Tue Feb 03, 6:45AM CST
CGEN: 8.19 (+0.08)
Compugen Fourth Quarter and Year-End 2014 Conference Call Scheduled for Tuesday, February 10, 2015 at 10:00 AM EST
Business Wire - Tue Feb 03, 6:09AM CST
Compugen Ltd. (NASDAQ: CGEN) today announced that the Company will host a conference call at 10:00 AM EST on Tuesday, February 10, 2015 to review fourth quarter and year-end 2014 results. Compugen participants on the conference call will include Martin Gerstel, Chairman; Dr. Anat Cohen-Dayag, President and CEO; and Ari Krashin, CFO. The quarterly and year-end results will be released on the Company's website (www.cgen.com), prior to the call.
CGEN: 8.19 (+0.08)
Compugen to Present Cancer Immunotherapy Targets at Two Tumor Immunology Conferences This Month
Business Wire - Mon Feb 02, 6:39AM CST
Compugen Ltd. (NASDAQ: CGEN) today announced that it will present aspects of its immune checkpoint related research at two scientific conferences this month.
CGEN: 8.19 (+0.08)
CGEN, RIGL, SPRT, AMRN, STON, PFH Are Seasonally Ripe To Go Down In the Next Five Weeks
M2 - Mon Feb 02, 4:02AM CST
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Compugen Ltd (NASDAQ:CGEN), Rigel Pharmaceuticals Inc (NASDAQ:RIGL), Support.com Inc (NASDAQ:SPRT), Amarin Corp PLC (NASDAQ:AMRN), Stonemor Partners L.P. (NASDAQ:STON), Corporate Asset Backed Corp (NYSE
FH) and each have a high seasonal probability to go Down in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at:
STON: 28.02 (-0.32), AMRN: 1.18 (unch), SPRT: 1.78 (+0.04), CGEN: 8.19 (+0.08), PFH: 18.56 (+0.36), RIGL: 2.47 (+0.05)
Pulmonary Fibrosis Therapeutic Pipeline Companies and Drugs Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Mon Jan 26, 9:32AM CST
The report "Pulmonary Fibrosis - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Pulmonary Fibrosis. Pulmonary Fibrosis is a breathing disorder. It is caused primarily because of the Lung tissues getting damaged. The lung tissues are affected with scars and this leads to the overall respiratory problem. The patient has serious breathing problem if he is dealing with this disorder. The key issue that the body faces internally is that of lack of oxygen due to thickening of the walls. Since the oxygen supply is reduced the patient has serious issues respirating. Complete report is available at http://www.rnrmarketresearch.com/pulmonary-fi...eport.html .
BIIB: 391.66 (-0.45), PSTI: 2.91 (+0.01), ASPX: 65.76 (+2.76), LPTN: 2.97 (-0.01), IBIO: 0.90 (+0.36), FGEN: 30.25 (+0.50), AQXP: 10.29 (-0.54), ITMN: 73.89 (-0.02), GALT: 3.84 (+0.16), LLY: 70.56 (+0.03), BMY: 60.04 (+0.56), GSK: 47.94 (+1.99), GILD: 101.90 (+1.10), CGEN: 8.19 (+0.08), FPRX: 24.63 (+0.63), CELGZ: 3.17 (-0.04)
Neviah Genomics Achieves Key Development Milestone for PropheTox(TM) Bioassay for Early Prediction of Drug-Induced Liver Toxicity and Secures Additional Financing
Business Wire - Mon Jan 12, 6:00AM CST
Neviah Genomics announced today that it had discovered and experimentally validated a set of biomarkers for the early detection of chronic drug-induced liver toxicity. Based on these results, the company is moving toward the further development of its PropheTox(TM) Bioassay, targeting 2016 for its commercial introduction. Neviah Genomics was jointly established in 2012 by Merck Serono, the biopharmaceutical business of Merck, and Compugen, and is operating from MS Ventures' Israel Bioincubator in Yavne, Israel.
MRK: 58.81 (-0.07), CGEN: 8.19 (+0.08)
20.2% Return Seen to Date on SmarTrend Compugen Call (CGEN)
Comtex SmarTrend(R) - Fri Jan 09, 9:10AM CST
SmarTrend identified an Uptrend for Compugen (NASDAQ:CGEN) on December 5th, 2014 at $7.77. In approximately 1 month, Compugen has returned 20.21% as of today's recent price of $9.34.
CGEN: 8.19 (+0.08)
Compugen Finance: Awards Honour Partners and Celebrate $1M Donated to Charity Through Green4Good
Marketwire Canada - Tue Jan 06, 9:00AM CST
Compugen Finance is pleased to announce the recipients of the 2014 Green4Good Partner Awards on Thursday evening, December 11 at Evergreen Brickworks, Don Valley, Toronto. The awards were given at a celebration honouring cumulative donations of $1M to charities through Green4Good. Many of the donor and recipient organizations were represented among the attendees. Green4Good, a program that turns end-of-first-lifea"c IT assets into cash for charities, began in 2009 and is now entering its sixth year of operations.
CGEN: 8.19 (+0.08)
Compugen Discloses Initial Experimental Results for Predicted Antibody Drug Conjugate Targets
Business Wire - Mon Jan 05, 6:14AM CST
Compugen Ltd. (NASDAQ: CGEN) announced today positive initial experimental results for the first two of five in silico predicted targets for antibody drug conjugate (ADC) cancer therapy disclosed in late 2013. The two candidates demonstrate low expression levels in normal critical tissues, such as heart and liver, and higher expression in multiple cancer types, such as colorectal and prostate cancers, for which there is high unmet medical need. These results suggest that the two target candidates may serve for the development of ADC therapy in oncology. Initial validation of the remaining three candidates, and further testing of these two, is ongoing. It is expected that a therapeutic antibody discovery program against a selected ADC target will commence later this year.
CGEN: 8.19 (+0.08)
Hypertension - Pipeline Review, H2 2014
M2 - Fri Jan 02, 4:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/hcv5ff/hypertension) has announced the addition of the "Hypertension - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hypertension and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Hypertension - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Hypertension pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Ahn-Gook Pharmaceutical - Beijing Labsolutions Pharmaceuticals - BioLineRx - Biocon Limited - CJ CheilJedang - Chong Kun Dang Pharmaceutical - Compugen - Cytokinetics - Daewoong Pharmaceutical - Daiichi Sankyo Company - DiaMedica - Dong-A Socio - Eli Lilly and Company - GlaxoSmithKline - HanAll Biopharma - IntelGenx - LG Life Sciences - Medivir - Merck & Co - Mitsubishi Tanabe Pharma Corporation - Novartis - Palatin Technologies - Pharmazz - Sanofi - Takeda Pharmaceutical Company - Teva Pharmaceutical Industries - Toray Industries - Torrent Pharmaceuticals - Yuhan Corporation - Yungjin For more information visit http://www.researchandmarkets.com/research/hc...pertension
LLY: 70.56 (+0.03), GSK: 47.94 (+1.99), MRK: 58.81 (-0.07), CGEN: 8.19 (+0.08), PTN: 0.72 (-0.02), TEVA: 56.77 (-0.58), NVS: 102.20 (-0.17)
Compugen Shares Up 12.0% Since SmarTrend's Buy Recommendation (CGEN)
Comtex SmarTrend(R) - Mon Dec 22, 10:00AM CST
SmarTrend identified an Uptrend for Compugen (NASDAQ:CGEN) on December 5th, 2014 at $7.77. In approximately 2 weeks, Compugen has returned 11.97% as of today's recent price of $8.70.
CGEN: 8.19 (+0.08)
Compugen (CGEN) Worth a Look: Stock Adds 5.5% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Dec 19, 7:30AM CST
Compugen Ltd. (CGEN) was a big mover last session, as the company saw its shares rise over 5% on the day.
CGEN: 8.19 (+0.08), AFFX: 11.45 (+0.02)
Direction of Market Influences: Special Research on Insperity, Compugen, Aeropostale, Starwood Hotels & Resorts, and Coca-Cola
PR Newswire - Wed Feb 11, 8:10AM CST
Editor Note: For more information about this release, please scroll to bottom.
KO: 41.99 (-0.18), NSP: 48.91 (+1.20), CGEN: 8.19 (+0.08), ARO: 3.63 (+0.04), HOT: 78.55 (+0.67)
Compugen's (CGEN) CEO Anat Cohen-Dayag on Q4 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Tue Feb 10, 12:49PM CST
CGEN: 8.19 (+0.08)
Premarket Gainers / Losers as of 9:10 am
Seeking Alpha - at Seeking Alpha - Tue Feb 10, 8:16AM CST
CAMT: 3.08 (+0.09), ZIOP: 9.64 (-0.35), XON: 39.30 (+1.05), BIOC: 1.41 (+0.22), KKR: 24.42 (+0.06), NBG: 1.61 (+0.18), ARO: 3.63 (+0.04), ANFI: 8.84 (-0.42), HOT: 78.55 (+0.67), COUP: 11.06 (-0.07), URBN: 38.47 (+0.27), VSTM: 7.93 (-0.44), SYN: 2.13 (+0.18), ANTH: 3.84 (+0.06), SALE: 16.41 (+0.13), CGEN: 8.19 (+0.08), DF: 16.19 (-0.11), CJJD: 2.59 (-0.01), MERU: 2.74 (-0.01)
Compugen reports 4Q loss
Automated Insights - Tue Feb 10, 6:36AM CST
TEL AVIV, Israel (AP) _ Compugen Ltd. (CGEN) on Tuesday reported a loss of $1.5 million in its fourth quarter.
CGEN: 8.19 (+0.08)
Compugen beats by $0.08, beats on revenue
Seeking Alpha - at Seeking Alpha - Tue Feb 10, 6:16AM CST
CGEN: 8.19 (+0.08)
Compugen Ltd. Reports Fourth Quarter and Calendar 2014 Results
Business Wire - Tue Feb 10, 6:10AM CST
Compugen Ltd. (NASDAQ: CGEN) today reported financial results for the fourth quarter and year ended December 31, 2014.
CGEN: 8.19 (+0.08)
Compugen: A Biotech With Many Rewarding Catalysts
Clinically Sound Investor - at Seeking Alpha - Tue Feb 10, 4:23AM CST
CGEN: 8.19 (+0.08)
Compugen Presents New Results Supporting CGEN-15049 as Potential Cancer Immunotherapy Target
Business Wire - Mon Feb 09, 6:14AM CST
Speaking today at the Keystone Symposia on Tumor Immunology in Banff, Canada, Arthur Machlenkin, PhD, Head of Immunology Group at Compugen Ltd. (NASDAQ: CGEN), presented new experimental results for CGEN-15049, a novel immune checkpoint protein discovered by the Company as a target for cancer immunotherapy. The new data presented for CGEN-15049 demonstrate expression of this protein on tumors isolated from ovarian cancer patients, both on the cancer cells and on immune cells within the tumor. Additional new data also demonstrate expression of CGEN-15049 on a similar population of tumor infiltrating immune cells in tumor-bearing mice. The collective data generated to date by Compugen support the ability of CGEN-15049 to affect key components of the immune system known to be involved in anti-tumor immune responses, supporting its potential as a promising target for immuno-oncology antibody therapy. Dr. Machlenkin's presentation at the Keystone Symposia also included experimental data for CGEN-15027, a different novel immune checkpoint candidate discovered by the Company.
CGEN: 8.19 (+0.08)
Compugen reports February 10
Seeking Alpha - at Seeking Alpha - Tue Feb 03, 6:45AM CST
CGEN: 8.19 (+0.08)
Compugen Fourth Quarter and Year-End 2014 Conference Call Scheduled for Tuesday, February 10, 2015 at 10:00 AM EST
Business Wire - Tue Feb 03, 6:09AM CST
Compugen Ltd. (NASDAQ: CGEN) today announced that the Company will host a conference call at 10:00 AM EST on Tuesday, February 10, 2015 to review fourth quarter and year-end 2014 results. Compugen participants on the conference call will include Martin Gerstel, Chairman; Dr. Anat Cohen-Dayag, President and CEO; and Ari Krashin, CFO. The quarterly and year-end results will be released on the Company's website (www.cgen.com), prior to the call.
CGEN: 8.19 (+0.08)
Compugen to Present Cancer Immunotherapy Targets at Two Tumor Immunology Conferences This Month
Business Wire - Mon Feb 02, 6:39AM CST
Compugen Ltd. (NASDAQ: CGEN) today announced that it will present aspects of its immune checkpoint related research at two scientific conferences this month.
CGEN: 8.19 (+0.08)
CGEN, RIGL, SPRT, AMRN, STON, PFH Are Seasonally Ripe To Go Down In the Next Five Weeks
M2 - Mon Feb 02, 4:02AM CST
BUYINS.NET / www.squeezetrigger.com is monitoring the Seasonality of Compugen Ltd (NASDAQ:CGEN), Rigel Pharmaceuticals Inc (NASDAQ:RIGL), Support.com Inc (NASDAQ:SPRT), Amarin Corp PLC (NASDAQ:AMRN), Stonemor Partners L.P. (NASDAQ:STON), Corporate Asset Backed Corp (NYSE
FH) and each have a high seasonal probability to go Down in the next weeks. By identifying stocks that are poised to go up or down based on seasonal tendencies, traders can increase their odds of making money. SqueezeTrigger.com is able to analyze over 20 years of data in less than 1 second for any stock in the market and determine if the stock has a long or short seasonal bias, how many trading days the move is expected to last, the probability of that move and the percentage move the stock is expected to make based on the seasonal bias. The technology used to generate these predictions is available for a low monthly fee at: STON: 28.02 (-0.32), AMRN: 1.18 (unch), SPRT: 1.78 (+0.04), CGEN: 8.19 (+0.08), PFH: 18.56 (+0.36), RIGL: 2.47 (+0.05)
Pulmonary Fibrosis Therapeutic Pipeline Companies and Drugs Review H1 2015 Report at RnRMarketResearch.com
PRWeb - Mon Jan 26, 9:32AM CST
The report "Pulmonary Fibrosis - Pipeline Review, H1 2015" provides comprehensive information on the therapeutic development for Pulmonary Fibrosis. Pulmonary Fibrosis is a breathing disorder. It is caused primarily because of the Lung tissues getting damaged. The lung tissues are affected with scars and this leads to the overall respiratory problem. The patient has serious breathing problem if he is dealing with this disorder. The key issue that the body faces internally is that of lack of oxygen due to thickening of the walls. Since the oxygen supply is reduced the patient has serious issues respirating. Complete report is available at http://www.rnrmarketresearch.com/pulmonary-fi...eport.html .
BIIB: 391.66 (-0.45), PSTI: 2.91 (+0.01), ASPX: 65.76 (+2.76), LPTN: 2.97 (-0.01), IBIO: 0.90 (+0.36), FGEN: 30.25 (+0.50), AQXP: 10.29 (-0.54), ITMN: 73.89 (-0.02), GALT: 3.84 (+0.16), LLY: 70.56 (+0.03), BMY: 60.04 (+0.56), GSK: 47.94 (+1.99), GILD: 101.90 (+1.10), CGEN: 8.19 (+0.08), FPRX: 24.63 (+0.63), CELGZ: 3.17 (-0.04)
Neviah Genomics Achieves Key Development Milestone for PropheTox(TM) Bioassay for Early Prediction of Drug-Induced Liver Toxicity and Secures Additional Financing
Business Wire - Mon Jan 12, 6:00AM CST
Neviah Genomics announced today that it had discovered and experimentally validated a set of biomarkers for the early detection of chronic drug-induced liver toxicity. Based on these results, the company is moving toward the further development of its PropheTox(TM) Bioassay, targeting 2016 for its commercial introduction. Neviah Genomics was jointly established in 2012 by Merck Serono, the biopharmaceutical business of Merck, and Compugen, and is operating from MS Ventures' Israel Bioincubator in Yavne, Israel.
MRK: 58.81 (-0.07), CGEN: 8.19 (+0.08)
20.2% Return Seen to Date on SmarTrend Compugen Call (CGEN)
Comtex SmarTrend(R) - Fri Jan 09, 9:10AM CST
SmarTrend identified an Uptrend for Compugen (NASDAQ:CGEN) on December 5th, 2014 at $7.77. In approximately 1 month, Compugen has returned 20.21% as of today's recent price of $9.34.
CGEN: 8.19 (+0.08)
Compugen Finance: Awards Honour Partners and Celebrate $1M Donated to Charity Through Green4Good
Marketwire Canada - Tue Jan 06, 9:00AM CST
Compugen Finance is pleased to announce the recipients of the 2014 Green4Good Partner Awards on Thursday evening, December 11 at Evergreen Brickworks, Don Valley, Toronto. The awards were given at a celebration honouring cumulative donations of $1M to charities through Green4Good. Many of the donor and recipient organizations were represented among the attendees. Green4Good, a program that turns end-of-first-lifea"c IT assets into cash for charities, began in 2009 and is now entering its sixth year of operations.
CGEN: 8.19 (+0.08)
Compugen Discloses Initial Experimental Results for Predicted Antibody Drug Conjugate Targets
Business Wire - Mon Jan 05, 6:14AM CST
Compugen Ltd. (NASDAQ: CGEN) announced today positive initial experimental results for the first two of five in silico predicted targets for antibody drug conjugate (ADC) cancer therapy disclosed in late 2013. The two candidates demonstrate low expression levels in normal critical tissues, such as heart and liver, and higher expression in multiple cancer types, such as colorectal and prostate cancers, for which there is high unmet medical need. These results suggest that the two target candidates may serve for the development of ADC therapy in oncology. Initial validation of the remaining three candidates, and further testing of these two, is ongoing. It is expected that a therapeutic antibody discovery program against a selected ADC target will commence later this year.
CGEN: 8.19 (+0.08)
Hypertension - Pipeline Review, H2 2014
M2 - Fri Jan 02, 4:30AM CST
Research and Markets (http://www.researchandmarkets.com/research/hcv5ff/hypertension) has announced the addition of the "Hypertension - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hypertension and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Hypertension - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Hypertension pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Ahn-Gook Pharmaceutical - Beijing Labsolutions Pharmaceuticals - BioLineRx - Biocon Limited - CJ CheilJedang - Chong Kun Dang Pharmaceutical - Compugen - Cytokinetics - Daewoong Pharmaceutical - Daiichi Sankyo Company - DiaMedica - Dong-A Socio - Eli Lilly and Company - GlaxoSmithKline - HanAll Biopharma - IntelGenx - LG Life Sciences - Medivir - Merck & Co - Mitsubishi Tanabe Pharma Corporation - Novartis - Palatin Technologies - Pharmazz - Sanofi - Takeda Pharmaceutical Company - Teva Pharmaceutical Industries - Toray Industries - Torrent Pharmaceuticals - Yuhan Corporation - Yungjin For more information visit http://www.researchandmarkets.com/research/hc...pertension
LLY: 70.56 (+0.03), GSK: 47.94 (+1.99), MRK: 58.81 (-0.07), CGEN: 8.19 (+0.08), PTN: 0.72 (-0.02), TEVA: 56.77 (-0.58), NVS: 102.20 (-0.17)
Compugen Shares Up 12.0% Since SmarTrend's Buy Recommendation (CGEN)
Comtex SmarTrend(R) - Mon Dec 22, 10:00AM CST
SmarTrend identified an Uptrend for Compugen (NASDAQ:CGEN) on December 5th, 2014 at $7.77. In approximately 2 weeks, Compugen has returned 11.97% as of today's recent price of $8.70.
CGEN: 8.19 (+0.08)
Compugen (CGEN) Worth a Look: Stock Adds 5.5% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Dec 19, 7:30AM CST
Compugen Ltd. (CGEN) was a big mover last session, as the company saw its shares rise over 5% on the day.
CGEN: 8.19 (+0.08), AFFX: 11.45 (+0.02)
